Cover Image

Rare cytogenetic abnormalities and alteration of microRNAs in acute myeloid leukemia and response to therapy

Mohammad Shahjahani, Elham Khodadi, Mohammad Seghatoleslami, Javad Mohammadi Asl, Neda Golchin, Zeynab Deris Zaieri, Najmaldin Saki
  • Mohammad Shahjahani
    Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Elham Khodadi
    Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Mohammad Seghatoleslami
    Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Javad Mohammadi Asl
    Department of Medical Genetics, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Neda Golchin
    Noor Clinical & Specialty Laboratory, Ahvaz, Iran, Islamic Republic of
  • Zeynab Deris Zaieri
    Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of
  • Najmaldin Saki
    Health Research Institute, Research Center of Thalassemia & Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of | najmaldinsaki@gmail.com

Abstract

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, which is heterogeneous in terms of morphological, cytogenetic and clinical features. Cytogenetic abnormalities, including karyotype aberrations, gene mutations and gene expression abnormalities are the most important diagnostic tools in diagnosis, classification and prognosis in acute myeloid leukemias. Based on World Health Organization (WHO) classification, acute myeloid leukemias can be divided to four groups. Due to the heterogeneous nature of AML and since most therapeutic protocols in AML are based on genetic alterations, gathering further information in the field of rare disorders as well as common cytogenetic abnormalities would be helpful in determining the prognosis and treatment in this group of diseases. Recently, the role of microRNAs (miRNAs) in both normal hematopoiesis and myeloid leukemic cell differentiation in myeloid lineage has been specified. miRNAs can be used instead of genes for AML diagnosis and classification in the future, and can also play a decisive role in the evaluation of relapse as well as response to treatment in the patients. Therefore, their use in clinical trials can affect treatment protocols and play a role in therapeutic strategies for these patients. In this review, we have examined rare cytogenetic abnormalities in different groups of acute myeloid leukemias according to WHO classification, and the role of miRNA expression in classification, diagnosis and response to treatment of these disorders has also been dealt with.

Keywords

rare abnormalities, microRNAs, therapy, acute myeloid leukemia.

Full Text

PDF
HTML
Submitted: 2014-08-06 23:26:31
Published: 2015-03-09 11:46:57
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
1674

Views:
PDF
500
HTML
729

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2015 Mohammad Shahjahani, Elham Khodadi, Mohammad Seghatoleslami, Javad Mohammadi Asl, Neda Golchin, Zeynab Deris Zaieri, Najmaldin Saki

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185